<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:01:57 -0700</creation_date>
  <update_date>2013-04-11 14:11:39 -0600</update_date>
  <accession>HMDBP02052</accession>
  <secondary_accessions>
    <accession>7531</accession>
    <accession>HMDBP03926</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>ATP-binding cassette sub-family B member 11</synonym>
  </synonyms>
  <gene_name>ABCB11</gene_name>
  <general_function>Involved in ATP binding</general_function>
  <specific_function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00036</accession>
      <name>Taurocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00307</accession>
      <name>1b-Hydroxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00308</accession>
      <name>3b-Hydroxy-5-cholenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00311</accession>
      <name>3b,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00312</accession>
      <name>3a,7a,12b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00316</accession>
      <name>2b,3a,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00320</accession>
      <name>3a,4b,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00326</accession>
      <name>1b,3a,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00328</accession>
      <name>12-Ketodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00330</accession>
      <name>3a,4b,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00340</accession>
      <name>3a,7a,12a,19-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00348</accession>
      <name>3b,12a-Dihydroxy-5a-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00359</accession>
      <name>3a,7a-Dihydroxycoprostanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00361</accession>
      <name>3b,7a-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00364</accession>
      <name>3a,6a,7b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00367</accession>
      <name>3a,6b,7b,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00371</accession>
      <name>1,3,12-Trihydroxycholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00376</accession>
      <name>3b,7a,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00377</accession>
      <name>3a,6b,7b,12b-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00381</accession>
      <name>Allolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00384</accession>
      <name>3a,7a-Dihydroxycholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00385</accession>
      <name>12a-Hydroxy-3-oxocholadienic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00390</accession>
      <name>3a,7b,12b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00391</accession>
      <name>7-Ketodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00395</accession>
      <name>3b,7b,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00399</accession>
      <name>3a,6b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00400</accession>
      <name>3,7-Dihydroxy-12-oxocholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00404</accession>
      <name>2b,3a,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00411</accession>
      <name>3a,12b-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00414</accession>
      <name>1b,3a,7a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00415</accession>
      <name>3a,6b,7b-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00419</accession>
      <name>3b,7a,12a-Trihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00427</accession>
      <name>3b,7b,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00432</accession>
      <name>3a,7b,12a-Trihydroxy-5a-Cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00433</accession>
      <name>1,3,7,12-Tetrahydroxycholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00437</accession>
      <name>3a,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00438</accession>
      <name>3b,12a-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00447</accession>
      <name>7a,12a-Dihydroxy-3-oxo-4-cholenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00460</accession>
      <name>7-Hydroxy-3-oxocholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00467</accession>
      <name>Nutriacholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00476</accession>
      <name>3-Oxo-4,6-choladienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00478</accession>
      <name>Allodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00502</accession>
      <name>3-Oxocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00503</accession>
      <name>7a-Hydroxy-3-oxo-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00505</accession>
      <name>Allocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00506</accession>
      <name>Alpha-Muricholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00514</accession>
      <name>Allochenodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00518</accession>
      <name>Chenodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00527</accession>
      <name>6a,12a-Dihydroxylithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00545</accession>
      <name>Chenodeoxycholic acid disulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00601</accession>
      <name>Coprocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00619</accession>
      <name>Cholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00626</accession>
      <name>Deoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00659</accession>
      <name>Deoxycholic acid disulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00664</accession>
      <name>Isohyodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00686</accession>
      <name>Isoursodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00713</accession>
      <name>Isoallolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00717</accession>
      <name>Isolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00733</accession>
      <name>Hyodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00760</accession>
      <name>Hyocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00761</accession>
      <name>Lithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00811</accession>
      <name>Murocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00865</accession>
      <name>Muricholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00907</accession>
      <name>Sulfolithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00917</accession>
      <name>Ursocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00946</accession>
      <name>Ursodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01181</accession>
      <name>4a-Carboxy-4b-methyl-5a-cholesta-8,24-dien-3b-ol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02082</accession>
      <name>Bisnorcholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02163</accession>
      <name>Trihydroxycoprostanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02195</accession>
      <name>Varanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02421</accession>
      <name>7-Sulfocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02430</accession>
      <name>(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-3-yl-b-D-Glucopyranosiduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02431</accession>
      <name>12b-Hydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02451</accession>
      <name>7b,12a-Dihydroxycholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02488</accession>
      <name>7a,12b-dihydroxy-5b-Cholan-24-oic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02492</accession>
      <name>7a-Hydroxy-5b-cholanic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02497</accession>
      <name>Glycochenodeoxycholate-3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02504</accession>
      <name>3-Sulfodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02522</accession>
      <name>Chenodeoxycholic acid sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02536</accession>
      <name>Isodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02585</accession>
      <name>3b,12b-Dihydroxy-5b-cholanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02586</accession>
      <name>Chenodeoxycholic acid 3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02642</accession>
      <name>Ursodeoxycholic acid 3-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03873</accession>
      <name>3a,7a,12a-Trihydroxy-5b-cholestanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06898</accession>
      <name>Chenodeoxyglycocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14351</accession>
      <name>Reserpine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14534</accession>
      <name>Digoxin n</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14644</accession>
      <name>Cimetidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14699</accession>
      <name>Bosentan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14710</accession>
      <name>Vinblastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14831</accession>
      <name>Fluorescein</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14983</accession>
      <name>Clofazimine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15044</accession>
      <name>Quinidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01926</accession>
      <name>17a-Ethynylestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15132</accession>
      <name>Doxorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15179</accession>
      <name>Rifampin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15185</accession>
      <name>Novobiocin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15360</accession>
      <name>Paclitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15570</accession>
      <name>Fusidic Acid</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>primary active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>p-p-bond-hydrolysis-driven transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity, coupled to transmembrane movement of substances</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyrophosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside-triphosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:2</chromosome_location>
    <locus>2q24</locus>
    <gene_sequence>&gt;3966 bp
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>1321</residue_number>
    <molecular_weight>146405.8</molecular_weight>
    <theoretical_pi>6.52</theoretical_pi>
    <pfams>
      <pfam>
        <name>ABC_membrane</name>
        <pfam_id>PF00664</pfam_id>
      </pfam>
      <pfam>
        <name>ABC_tran</name>
        <pfam_id>PF00005</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>63-83</region>
      <region>148-168</region>
      <region>216-236</region>
      <region>241-261</region>
      <region>320-340</region>
      <region>354-374</region>
      <region>756-776</region>
      <region>795-815</region>
      <region>870-890</region>
      <region>891-911</region>
      <region>980-1000</region>
      <region>1012-1032</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</protein_sequence>
  </protein_properties>
  <genbank_protein_id>21536378</genbank_protein_id>
  <uniprot_id>O95342</uniprot_id>
  <uniprot_name>ABCBB_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_003742.2</genbank_gene_id>
  <genecard_id>ABCB11</genecard_id>
  <geneatlas_id>ABCB11</geneatlas_id>
  <hgnc_id>HGNC:42</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ: A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998 Nov;20(3):233-8.</reference_text>
      <pubmed_id>9806540</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31.</reference_text>
      <pubmed_id>15815621</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, De Jager-Krikken A, Kuipers F, Stellaard F, Bijleveld CM, Gouw A, Van Goor H, Thompson RJ, Muller M: Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999 Dec;117(6):1370-9.</reference_text>
      <pubmed_id>10579978</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet. 2002;47(1):38-50.</reference_text>
      <pubmed_id>11829140</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen HL, Chang PS, Hsu HC, Ni YH, Hsu HY, Lee JH, Jeng YM, Shau WY, Chang MH: FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels. J Pediatr. 2002 Jan;140(1):119-24.</reference_text>
      <pubmed_id>11815775</pubmed_id>
    </reference>
    <reference>
      <reference_text>van Mil SW, van der Woerd WL, van der Brugge G, Sturm E, Jansen PL, Bull LN, van den Berg IE, Berger R, Houwen RH, Klomp LW: Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004 Aug;127(2):379-84.</reference_text>
      <pubmed_id>15300568</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak-Ublick GA: Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004 Feb;14(2):91-102.</reference_text>
      <pubmed_id>15077010</pubmed_id>
    </reference>
    <reference>
      <reference_text>Noe J, Kullak-Ublick GA, Jochum W, Stieger B, Kerb R, Haberl M, Mullhaupt B, Meier PJ, Pauli-Magnus C: Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol. 2005 Sep;43(3):536-43.</reference_text>
      <pubmed_id>16039748</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, Stieger B, Kullak-Ublick GA, Kerb R: Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos. 2006 Sep;34(9):1582-99. Epub 2006 Jun 8.</reference_text>
      <pubmed_id>16763017</pubmed_id>
    </reference>
    <reference>
      <reference_text>Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology. 2006 Jul;44(1):62-74.</reference_text>
      <pubmed_id>16799996</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C: Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007 Jan;17(1):47-60.</reference_text>
      <pubmed_id>17264802</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81.</reference_text>
        <pubmed_id>12235261</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F: Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J Hepatol. 2002 Nov;37(5):556-63.</reference_text>
        <pubmed_id>12399219</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58.</reference_text>
        <pubmed_id>12404239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31.</reference_text>
        <pubmed_id>11343252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ: Physiological characteristics of allo-cholic acid.  J Lipid Res. 2003 Jan;44(1):84-92.</reference_text>
        <pubmed_id>12518026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Green RM, Hoda F, Ward KL: Molecular cloning and characterization of the murine bile salt export pump.  Gene. 2000 Jan 4;241(1):117-23.</reference_text>
        <pubmed_id>10607905</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998 Apr 17;273(16):10046-50.</reference_text>
        <pubmed_id>9545351</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98.</reference_text>
        <pubmed_id>11557132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y: Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta. 2001 Mar 9;1511(1):7-16.</reference_text>
        <pubmed_id>11248200</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localization of mrp6 in rat liver.  Mol Pharmacol. 2000 Mar;57(3):634-41.</reference_text>
        <pubmed_id>10692506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug       5.</reference_text>
        <pubmed_id>15297262</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholic acid</name>
        <accession>HMDB00619</accession>
      </metabolite>
      <reference>
        <reference_text>Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81.</reference_text>
        <pubmed_id>12235261</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholic acid</name>
        <accession>HMDB00619</accession>
      </metabolite>
      <reference>
        <reference_text>Green RM, Hoda F, Ward KL: Molecular cloning and characterization of the murine bile salt export pump.  Gene. 2000 Jan 4;241(1):117-23.</reference_text>
        <pubmed_id>10607905</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholic acid</name>
        <accession>HMDB00619</accession>
      </metabolite>
      <reference>
        <reference_text>Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug       5.</reference_text>
        <pubmed_id>15297262</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Deoxycholic acid</name>
        <accession>HMDB00626</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD: Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001 Oct 19;276(42):39411-8. Epub 2001 Aug 16.</reference_text>
        <pubmed_id>11509573</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bosentan</name>
        <accession>HMDB14699</accession>
      </metabolite>
      <reference>
        <reference_text>Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001 Apr;69(4):223-31.</reference_text>
        <pubmed_id>11309550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorescein</name>
        <accession>HMDB14831</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofazimine</name>
        <accession>HMDB14983</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72.</reference_text>
        <pubmed_id>10611165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Huang L, Smit JW, Meijer DK, Vore M: Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology. 2000 Jul;32(1):66-72.</reference_text>
        <pubmed_id>10869290</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58.</reference_text>
        <pubmed_id>12404239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Kemp DC, Brouwer KL: Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure. Toxicol In Vitro. 2004 Dec;18(6):869-77.</reference_text>
        <pubmed_id>15465654</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Horikawa M, Kato Y, Tyson CA, Sugiyama Y: Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18(1):16-22.</reference_text>
        <pubmed_id>15618715</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31.</reference_text>
        <pubmed_id>11343252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98.</reference_text>
        <pubmed_id>11557132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30.</reference_text>
        <pubmed_id>10648470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58.</reference_text>
        <pubmed_id>12404239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31.</reference_text>
        <pubmed_id>11343252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30.</reference_text>
        <pubmed_id>10648470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Novobiocin</name>
        <accession>HMDB15185</accession>
      </metabolite>
      <reference>
        <reference_text>Saito H, Osumi M, Hirano H, Shin W, Nakamura R, Ishikawa T: Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J. 2009 Sep;11(3):581-9. Epub 2009 Aug 18.</reference_text>
        <pubmed_id>19688600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44.</reference_text>
        <pubmed_id>12739759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics.  Toxicology. 2001 Oct 5;167(1):37-46.</reference_text>
        <pubmed_id>11557128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fusidic Acid</name>
        <accession>HMDB15570</accession>
      </metabolite>
      <reference>
        <reference_text>Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.</reference_text>
        <pubmed_id>12106615</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
